Discovery - University of Dundee - Online Publications

Library & Learning Centre

Modulation of L-alpha-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids

Modulation of L-alpha-Lysophosphatidylinositol/GPR55 Mitogen-activated Protein Kinase (MAPK) Signaling by Cannabinoids

Research output: Contribution to journalArticle

View graph of relations

Authors

  • Sharon Anavi-Goffer
  • Gemma Baillie
  • Andrew J. Irving
  • Juerg Gertsch
  • Iain R. Greig
  • Roger G. Pertwee
  • Ruth A. Ross

Research units

Info

Original languageEnglish
Pages91-104
Number of pages14
JournalJournal of Biological Chemistry
Journal publication date2 Jan 2012
Volume287
Issue1
DOIs
StatePublished

Abstract

GPR55 is activated by L-alpha-lysophosphatidylinositol (LPI) but also by certain cannabinoids. In this study, we investigated the GPR55 pharmacology of various cannabinoids, including analogues of the CB1 receptor antagonist Rimonabant (R), CB2 receptor agonists, and Cannabis sativa constituents. To test ERK1/2 phosphorylation, a primary downstream signaling pathway that conveys LPI-induced activation of GPR55, a high throughput system, was established using the AlphaScreen (R) SureFire (R) assay. Here, we show that CB1 receptor antagonists can act both as agonists alone and as inhibitors of LPI signaling under the same assay conditions. This study clarifies the controversy surrounding the GPR55-mediated actions of SR141716A; some reports indicate the compound to be an agonist and some report antagonism. In contrast, we report that the CB2 ligand GW405833 behaves as a partial agonist of GPR55 alone and enhances LPI signaling. GPR55 has been implicated in pain transmission, and thus our results suggest that this receptor may be responsible for some of the antinociceptive actions of certain CB2 receptor ligands. The phytocannabinoids Delta(9)-tetrahydrocannabivarin, cannabidivarin, and cannabigerovarin are also potent inhibitors of LPI. These Cannabis sativa constituents may represent novel therapeutics targeting GPR55.

Documents

Library & Learning Centre

Contact | Accessibility | Policy